PIK3CA and prostate cancer: For example, the phase 2 ProCAID trial in participants with metastatic castration-resistant prostate cancer identified that the addition of capivasertib to docetaxel chemotherapy improved overall survival in patients with PI3K/AKT/PTEN pathway-altered and pathway non-altered tumours,30 and a phase 3 trial of another AKT inhibitor (ipatasertib) combined with abiraterone found efficacy in participants with PTEN-deficient metastatic castration-resistant prostate cancer and no treatment effect in the remainder of the study population.31